Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study by unknown
ORIGINAL RESEARCH ARTICLE
Tolerability of an Immunologically Enhanced Subcutaneous
Immunotherapy Preparation in Patients Treated
with Concomitant Allergy Immunotherapy: A Non-Interventional
Observational Study
Rainer Reiber1 • Hendrik Wolf2 • Jo¨rg Schnitker3 • Eike Wu¨stenberg2,4
Published online: 9 January 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Background For causal treatment by allergy immunother-
apy (AIT) a single or few allergen products for the clini-
cally most relevant allergens are applied to treat multiple
allergies, but few data on the tolerability of multiple AIT
applications are available.
Objective The aim of our study was to investigate safety
and tolerability in patients treated by subcutaneous
immunotherapy (SCIT) and concomitant SCIT or sublin-
gual immunotherapy (SLIT) products.
Methods In a non-interventional, observational study in
Germany treatment of patients with a primary SCIT and
concomitant AIT (SCIT or SLIT) was documented during
the first 4 months of treatment. Adverse events (AEs) were
recorded by the physicians and by patients in diaries, and
coded using the Medical Dictionary for Regulatory
Activities (MedDRA).
Results Three hundred and seven patients were treated
with the primary SCIT by 79 allergists, and 271 received
a concomitant AIT. AEs were reported in 92 (33.9%)
patients and adverse drug reactions (ADRs) in 63
(23.2%) patients related to the primary SCIT and in 69
(25.5%) to the concomitant AIT; six (2.2%) patients
discontinued due to ADRs. ADRs were mild or moderate
in 40 (14.8%) patients, severe in 23 (8.5%), and serious
in one patient. The most frequent reactions were local
swelling and pruritus. Overall tolerability was assessed
as ‘good’ or ‘very good’ by 95.6% of patients and 96.7%
of physicians.
Conclusions Compared with data from a large previous
study no increase in the frequency of ADRs in real life or
change in the tolerability profile was observed for SCIT
with concomitant SCIT or SLIT.
Key Points
Tolerability of subcutaneous allergy immunotherapy
was not affected if applied with concomitant allergy
immunotherapy products.
Treatment with more than one product appears not to
impair overall safety and tolerability.
1 Introduction
A high proportion of allergic patients with respiratory
allergy and manifesting as allergic rhinoconjunctivitis with
or without allergic asthma are poly-sensitized in accor-
dance with the spectrum of allergens patients are exposed
to in their geographical region [1].
For poly-sensitized patients who suffer from more than
one essential clinically relevant allergy adequate treatment
with specific immunotherapy is challenging. The approa-
ches for allergy immunotherapy are different in Europe and
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the USA. The European approach is that allergy
immunotherapy (AIT) products containing single allergens
are used and one or a few different allergen products are
applied to treat the clinically most important seasonal and/
or perennial allergies [2, 3].
The majority of patients treated by AIT in Germany are
given subcutaneous injections, but sublingual
immunotherapy (SLIT) as liquid formulations or tablets,
currently available with grass and house dust mite aller-
gens, are being used more and more often. Only a few
reports on systematically recorded data for tolerability of
simultaneous application of more than one AIT product are
currently available [4]. The tolerability of treatment with
the SQ grass SLIT-tablet when applied with concomitant
AIT has been investigated in a separate study. No change
in the tolerability profile and frequency of reactions with
the SQ grass SLIT-tablet has been observed [5].
The aim of the present study was to investigate whether
tolerability of treatment with an immunologically enhanced
subcutaneous immunotherapy (SCIT) product (AVANZ)
is influenced when applied with concomitant AIT in the
real-life setting. The SCIT product primarily applied in this
study was a short up-dosed (by five injections) immuno-
logically enhanced formulation with an optimized allergen
to aluminium hydroxide ratio allowing the administration
of lower doses for maintenance treatment. This treatment
has been shown to induce similar immunological effects
[6–8] to the traditional SCIT product of the same SQ
standardized composition with a longer up-dosing period
and a higher allergen concentration for maintenance
treatment (Alutard SQ/ALK-depot SQ). In a multicentre
phase II/III trial in Spain with the immunologically
enhanced SCIT product (AVANZ Phleum) it was found
that the total number of adverse drug reactions (ADRs) was
associated with the number of grass allergens to which the
patients were sensitized [9].
2 Methods
2.1 Study Design
This study was multicentre, open, uncontrolled, and
observational according to non-interventional post-autho-
rization surveillance studies mentioned in the German drug
law for recording of data concerning tolerability and rou-
tine application of drugs after marketing authorization.
These studies are explicitly excluded from the application
of EU guidelines on clinical trials [10] and are, thus, not
conducted according to Good Clinical Practice (GCP)
guidelines [11].
All patients included were treated with the immuno-
logically enhanced SCIT product (AVANZ, ALK-Abello´,
Denmark) following the specifications for administration in
the summary of product characteristics (SmPC) [12]. Data
were analysed by epidemiological methods. Centres were
distributed all over Germany and were asked to record data
on patients in a consecutive order dependent on the
patient’s willingness to participate in the study in order to
avoid a selection bias.
Documentation was started at first administration of
the primary SCIT (visit 1). Subsequently, all further
SCIT injections were entered in an injection protocol and
any adverse events (AEs) due to the SCIT and/or the
concomitant AIT were recorded up to a total observation
period of about 4 months. Documentation was completed
at a second visit (V2) at the end of the observation
period. A diagrammatic outline of the study is shown in
Fig. 1.
2.2 Allergy Immunotherapy
All patients included in the study received treatment with
the immunologically enhanced SCIT product AVANZ
(ALK, Denmark) using one of the following allergens: tree
mix (hazel/alder/birch), birch, grass mix and rye (Dactylis
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Fig. 1 Diagrammatic representation of the study. Primary SCIT
(AVANZ) was up-dosed according to the summary of product
characteristics with five injections in weekly intervals and when the
maintenance dose was reached the injection interval was increased
stepwise by 2 weeks (a) to an injection interval of 6 ± 2 weeks
(b) and (c). SCIT subcutaneous immunotherapy
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glomerata/Festuca pratensis/Lolium perenne/Phleum pra-
tense/Secale cereale), Phleum pratense, mugwort, mite
mix (Dermatophagoides pteronyssinus/Dermatophagoides
farinae) or Alternaria alternata as primary AIT.
Treatment was initiated between September 2012 and
January 2014. According to the SmPC of AVANZ [12],
SCIT is initiated by a five-step up-dosing schedule (300,
600, 3,000, 6,000, 15,000 SQ?) with injection intervals of
1 week. When the maintenance dose has been reached the
injection interval is increased stepwise by 2 weeks to an
injection interval of 6 ± 2 weeks (Fig. 1).
2.3 Ethics, Consent and Permissions
According to German drug law, non-interventional post-
marketing studies have to be notified to the authorities. The
study was approved by the Ethics Committee of the Lan-
desa¨rztekammer Baden-Wu¨rttemberg (Reference No.
F-2012-043) and consent from the patients for collection of
their data was obtained. The decision by the physician to
prescribe SCIT as primary AIT and concomitant AIT was
taken independently from the inclusion of the patient in the
study. For recording and evaluation of data, patients were
assigned a three-digit patient number. Direct identification
of the patients was restricted to the physicians’ offices that
participated in the study.
2.4 Patients
In the study 307 patients were included by 79 allergists
distributed around Germany. Adult patients (C18 years)
with a diagnosis of rhinitis and/or conjunctivitis (according
to symptoms, skin prick test or specific IgE measurement)
with or without asthma with clinically relevant symptoms
that were treated with AVANZ and a concomitant AIT
(SCIT or SLIT) who had no contraindications to a pre-
scription according to the SmPC of AVANZ [12] were
eligible to be documented in this study.
Indications according to the SmPC are: treatment of
allergic rhinoconjunctivitis in patients with allergy with or
without mild to moderate asthma. Contraindications were:
immunopathological conditions such as immune complex
and immunodeficiency diseases and autoimmune diseases,
diseases or conditions preventing the treatment of possible
anaphylactic reactions, e.g. chronic heart and lung diseases,
severe arterial hypertension and treatment with b-receptor-
blockers, malignancies, renal dysfunction/impairment,
uncontrolled or severe asthma (in adults: a FEV1\70% of
predicted value after adequate pharmacological treatment,
in children: a FEV1\80% of predicted value after ade-
quate pharmacological treatment), and known hypersensi-
tivity to any of the excipients.
2.5 Assessments
The time schedule and the major assessments of the study
are shown in Fig. 1.
Upon inclusion of the patient at visit 1 (V1) demo-
graphic data and data on the allergy history including age
at first appearance of symptoms, clinical manifestation of
the allergy (rhinitis/conjunctivitis/asthma/atopic dermati-
tis), other allergies, the diagnostics performed, any previ-
ous AIT, and concomitant treatments by AIT or other
medications due to concomitant diseases were recorded.
The currently used anti-allergic medication was recorded
(topical or oral antihistamines, nasal or oral corticosteroids,
inhaled corticosteroids, inhaled short-acting b2 agonists
(SABAs), inhaled long-acting b2 agonists (LABAs), and
other as specified).
The administration of any AIT was documented in the
case report form (CRF) by injection protocols of the pri-
mary SCIT and, if applicable, of a concomitant SCIT or by
recording the first application of a concomitant SLIT. The
administration of the AIT was completely recorded in
patient diaries including the primary SCIT and all con-
comitant AITs (SCIT and/or SLIT), if applicable.
During administration of AIT tolerability was assessed
based on AEs recorded by the physician at administration
in the office and by the patient in the diary. An AE was
defined as any untoward medical occurrence in a patient
who was treated with any AIT (primary or concomitant)
and which did not necessarily have a causal relationship
with treatment. AEs that were possibly related to treatment
were classified as ADRs of the primary SCIT or the con-
comitant AIT, respectively. When side effects occurred
during home treatment patients were instructed to record
the symptoms, the time of last administration of AIT and
the time of occurrence of the side effect, the severity (mild,
moderate or severe) and the actions taken due to the side
effects (no action, taking a medication—if yes, which
product and due to which symptoms?, visit to the doctor,
discontinuation of treatment, something else—if yes,
what?).
AEs were specified by the physician in the CRF as
diagnosis or description and assessed by severity (mild,
moderate or severe), causality (possible or unlikely),
change of treatment (no change, interruption or discontin-
uation), treatment with medication (yes, no), outcome
(recovered, recovered with sequelae, not recovered, fatal or
unknown) and seriousness (yes, no). An AE was assessed
as severe when the event considerably interfered with the
patient’s daily activities. A serious AE (SAE) was defined
as any medical occurrence or effect that was life-threat-
ening, required hospitalization or prolongation of hospi-
talization, resulted in persistent or significant disability or
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incapacity, resulted in death, congenital abnormalities or
birth defect, or any other event judged medically important.
After about 4 months of treatment the documentation
for the study was completed with a final visit (V2). At V2
the physician interviewed the patients with respect to side
effects that occurred between V1 and V2, i.e. during home
treatment with SLIT, if applicable, and recorded all AEs in
the CRF together with his medical assessment.
In addition, an overall assessment of tolerability (very
good, good, moderate or poor) was performed by patients
and physicians at V2, and the continuation or discontinu-
ation of treatment and its reasons were recorded.
SAEs were further documented on a separate report
form, and if applicable according to legal pharmacovigi-
lance procedures, they were reported to the authorities.
2.6 Statistics
Data analysis was performed solely by descriptive statistics
using minimum, maximum, median, mean, range and
standard deviation for continuous data as well as frequency
distributions for ordinal data. No imputation was per-
formed in case of missing data, but all available data were
used to their full extent. The principal statistical software
used was SAS, version 9.3.0.
No formal sample size calculation has been made for
this study. The primary objective was to record data on
safety and tolerability of the primary SCIT when applied
with concomitant AIT. In order to obtain a real-life picture
the study aimed to engage a large number of physicians in
the study who recorded data on patients who were routinely
treated with the primary SCIT and concomitant AIT. AEs
were coded according to the current version of the Medical
Dictionary for Regulatory Activities (MedDRA). ADRs
were displayed for patients and according to the level of
events including multiple occurrences by patient.
3 Results
3.1 Patients
The study was initiated in September 2012 and the last
patient completed the study in April 2014. Patient char-
acteristics and treatment with AIT are displayed in Table 1.
Treatment with the primary SCIT was recorded in 307
patients by 79 allergists. Treatment was discontinued in a
total of 23 (7.5%) patients, eight (2.6%) patients did not
return after the first injection of the primary SCIT, ten
(3.3%) patients discontinued due to AEs, two (0.7%)
patients discontinued due to non-compliance, two (0.7%)
patients withdrew their consent and one (0.3%) patient
moved. Treatment with the primary SCIT was continued at
the end of the observation period in 284 (92.5%) patients.
3.2 Treatment by AIT
It was intended that only data from patients who were
concomitantly treated with another AIT were recorded. In
36 patients, however, no concomitant AIT had been
applied. Therefore, the tolerability data are presented sep-
arately for patients with concomitant AIT (N = 271),
patients without concomitant AIT (N = 36) and total
patients (N = 307).
The majority of patients included in the study were
treated by one concomitant SCIT (69.4%), 26.9% of
patients received one concomitant SLIT (SLIT-tablet
21.0%, SLIT-drops 5.9%) and 3.7% of patients received
two concomitant AIT products (SCIT ? SLIT 3.0% and
SCIT ? SCIT 0.7%). Tree pollen allergens were applied as
primary SCIT in 146 (53.9%) patients, grass pollen aller-
gens in 66 (24.4%) and house dust mite allergens in 51
(18.8%) patients (mugwort: seven (2.6%) patients, Al-
ternaria alternata: one (0.4%) patient). The different
allergens used for treatment of patients as primary SCIT
and concomitant AIT (SCIT / SLIT) are shown in Table 2.
The most frequent allergens applied as concomitant AIT
were grass pollen, house dust mites and tree pollen. Con-
comitant treatment was started in 231 (86.8%) patients
before and at initiation of the primary SCIT, respectively,
and in 35 (13.2%) patients after the initiation of the pri-
mary SCIT.
3.3 Tolerability
A summary of all AEs and ADRs related to the primary
SCIT reported during the observation period is shown in
Table 3. The ADR rates were very similar in the group of
patients with concomitant AIT (23.2%) and in the group
without concomitant AIT (22.2%). In 40/271 (14.8%)
patients treated with the primary SCIT and concomitant
AIT, severity of ADRs to the primary SCIT was assessed
mild or moderate and assessed as severe in 23/271 (8.5%)
patients. Treatment with the primary SCIT was discontin-
ued due to ADRs in six (2.2%) patients with concomitant
AIT and in eight (2.6%) patients of all the patients inclu-
ded. The ADR rate was the same in adult patients and
patients\18 years of age (23.1%). In patients with a his-
tory of AIT the ADR rate was higher (36.7%) than in
patients without AIT in their history (20.3%). ADRs related
to the concomitant AIT, concomitant SCIT and concomi-
tant SLIT are shown in Table 4. No relevant differences
were observed for the rates of ADRs for patients treated
with concomitant SCIT, concomitant SLIT and SCIT/SLIT
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combinations. ADRs related to the primary SCIT, con-
comitant AIT, concomitant SCIT and concomitant SLIT
reported in two or more patients are displayed as MedDRA
System Organ Classes (SOCs) and Preferred Terms (PTs)
in Table 5. Most frequent reactions (C5% of patients)
assessed related to SCIT were pruritus (primary SCIT:
7.4% of patients, concomitant SCIT: 7.6%) and local
swelling (primary SCIT: 5.9%, concomitant SCIT: 7.6%).
Most frequent reactions assessed related to the concomitant
SLIT were throat irritation (8.6%), oral pruritus (6.2%) and
ear pruritus (6.2%). Serious AEs were reported in two
patients. A 34-year-old male patient treated with SCIT with
tree and grass pollen allergens (AVANZ tree mix and
AVANZ grass mix and rye) was hospitalized due to
pertussis. The event was assessed as being unlikely to be
related to AIT. In a 52-year-old female patient with med-
ical history of allergy to grass pollen, birch pollen and
house dust mites and symptoms of allergic rhinitis and
bronchial asthma, an AE was classified serious and asses-
sed as possibly related to treatment with the SCIT
(AVANZ Phleum pratense and AVANZ mite mix, up-
dosing injection no. 4, dose 3.000 SQ? for both products,
interval between injections 30 min) and concomitant SLIT
(STALORAL birch). Both injections had been applied
before onset of the SAE symptoms, and the time of SLIT
administration was not documented. In this patient a severe
systemic reaction with eyelid swelling, rough voice and
shortness of breath was reported and considered medically
important. The patient was treated for her asthma with a
combination of inhaled corticosteroids and beta-agonists
(fluticasone propionate and salmeterol). She recovered
after intravenous administration of corticosteroids, anti-
histamine and a volume substitute (NaCl) on the same day.
Due to the intravenous administration of steroids the event
was upgraded from a systemic reaction to an anaphylactic
reaction. AIT with both SCIT products was discontinued.
Overall tolerability in our study was assessed as ‘good’ or
‘very good’ by 95.6% of patients and 96.7% of physicians.
3.4 Compliance
Patient diaries could be evaluated in 239 (78.6%) of the
307 patients included in the study (three missing values)
and in 217 (80.4%) of the 271 patients (one missing value)
with a concomitant AIT. In 67 out of 81 patients who
received a concomitant SLIT (including eight patients with
SCIT and SLIT combinations) diary records could be
analysed that resulted in compliance rates with SLIT
of C80% in 40 (59.7%) patients, 50–79% in six (9.0%)
and\50% in 21 (31.3%) patients. In 254 (94.1%) out of
the 271 patients with primary SCIT and concomitant AIT
(one missing value) the patient performed the AITs as
instructed, but not in a further 16 (5.9%) patients (ap-
pointments not kept for injections: 12 patients; discontin-
ued: one patient; other reasons: three patients) according to
the physician’s assessment.







Patients, n 271 36 307
Age, years ± SD 36.5 ± 13.9 38.9 ± 12.9 36.8 ± 13.8
Patients 5–11 years, n (%) 5 (1.8) – 5 (1.6)
Patients 12–17 years, n (%) 8 (3.0) – 8 (2.6)
Patients C18 years, n (%) 258 (95.2) 36 (100.0) 294 (95.8)
Gender, n (%)
Male 129 (47.6) 12 (33.3) 141 (45.9)
Female 142 (52.4) 24 (66.7) 166 (54.1)
Age at first diagnosis of allergy,
years (±SD)
30.4 (±14.4) 36.7 (±13.3) 31.1 (±14.4)
Major manifestations, n (%)
Rhinitis 258 (95.2) 34 (94.4) 292 (95.1)
Conjunctivitis 184 (67.9) 27 (75.0) 211 (68.7)
Asthma 81 (29.9) 4 (11.1) 85 (27.7)
Atopic dermatitis 25 (9.2) 3 (8.3) 28 (9.1)
Concomitant allergies not treated in this
study, n (%)
165 (60.9) 19 (52.8) 184 (59.9)
History of AIT, n (%) 49 (18.1) 4 (11.1) 53 (17.3)
AIT allergy immunotherapy, SCIT subcutaneous immunotherapy, SD standard deviation
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4 Discussion
In this study investigating tolerability in 271 patients
treated concomitantly with more than one AIT product,
SCIT as primary treatment and SCIT or SLIT as con-
comitant treatment, patients most frequently received one
concomitant SCIT (69.4%), less frequently one concomi-
tant SLIT (26.9%) and only in rare cases two concomitant
AITs (3.7%) as combinations of SCIT and SLIT or two
SCIT products. Tree pollen (53.9%), grass pollen (24.4%)
and house dust mite allergens (18.8%) were predomi-
nantly applied as primary SCIT, and grass, house dust
mite and tree allergen products as concomitant AIT. AEs
were observed in 33.9% of 271 patients with primary
SCIT and concomitant AIT, and AEs assessed possibly
related (ADRs) to the primary SCIT in 23.2% of patients
and to the concomitant AIT in 25.5% (SCIT: 25.3%,
SLIT: 28.4%). The most frequent reactions (C5% of
patients) were pruritus and local swelling for treatment by
SCIT and throat irritation, oral pruritus and ear pruritus
for treatment by SLIT. ADRs to the primary SCIT were of
mild to moderate severity (14.8%) in the majority of all
patients with primary SCIT and concomitant AIT and less
frequently severe (8.5%). A systemic reaction in one
patient who suffered from allergic rhinoconjunctivitis and
bronchial asthma treated with two SCIT products (house
dust mite, timothy grass) and one SLIT product (birch)
with eyelid swelling, rough voice and shortness of breath
was assessed as medically important and, thus, classified
as serious; due to the application of intravenous corti-
costeroids the case was upgraded to MedDRA PT ana-
phylactic reaction. Treatment was discontinued due to
ADRs in 2.2% of patients who received the primary SCIT
and concomitant AIT.
The available safety data on treatment with more than
one allergen extract in patients with multiple allergies have
been reviewed by Passalaqua et al. [2] and Calderon et al.
[3]. The tolerability of a SCIT treatment by one single
allergen extract or two allergen extracts applied in parallel
has been investigated in a retrospective study including 147
patients who received injections with pollen, house dust
mite, mould, animal dander or hymenoptera venom aller-
gens. The rate of ADRs during the dose increase phase was
observed to be slightly higher in the group of patients that
had been treated by two injections given in parallel without
being significant [4].
Tolerability data have been recorded in a previous non-
interventional observational study in 1036 patients treated
with the same product as that applied as primary SCIT in
our study (AVANZ), predominantly using tree pollen,
grass pollen and house dust mite allergens during a 1-year
observation period; the proportion of patients who received
a concomitant AIT was 16% in that study [13], thus indi-
cating that the proportion of patients who are treated by
more than one AIT product in parallel in Germany appears
to be small. The proportion of patients with ADRs in our
study (24.5%) was not very different compared with the
previous study (20.8%), whereas the severity of ADRs was
classified in more patients as severe (8.5%) compared with
the data from the previous study (2.9%), possibly indicat-
ing a higher severity of ADRs when more than one AIT
product is applied, but comparison of data between the two
Table 2 Treatment of patients with primary SCIT and concomitant
AIT (SCIT, SLIT)
Patients with primary SCIT and concomitant AIT n %
Primary SCIT (AVANZ) 271 100.0
Tree mix 102 37.6
Birch 44 16.2
Grass mix and rye 60 22.1
Phleum pratense 6 2.2
House dust mite mix 51 18.8
Mugwort 7 2.6
Alternaria alternata 1 0.4
One concomitant SCIT 188 69.4
Grasses and rye 64 23.6
House dust mites 59 21.8
Trees (hazel/alder/birch) 46a 17.0
Weed pollen 6 2.2
Grasses and rye/trees 5 1.8
Grasses and rye/weed pollen 3 1.1
Moulds 3 1.1
Animal epithelia 1 0.4
Wasp venom 1 0.4
One concomitant SLIT 73 26.9
Concomitant SLIT-tablet (grass) 57 21.0
Concomitant SLIT-drops 16 5.9
Trees 7 2.6
House dust mites 7 2.6
Animal epithelia 1 0.4
Weed pollen 1 0.4
Concomitant SCIT ? SLIT-drops 4 1.5
Grass ? tree 2 0.7
Tree ? house dust mites 2 0.7
Concomitant SCIT ? SLIT-tablet 4 1.5
House dust mites ? grass tablet 3 1.1
Oak pollen ? grass tablet 1 0.4
Concomitant SCIT ? SCIT 2 0.7
Grass ? house dust mites 1 0.4
Trees ? moulds 1 0.4
AIT allergy immunotherapy, SCIT subcutaneous immunotherapy,
SLIT sublingual immunotherapy
a Including one patient treated with oak pollen
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different studies must be interpreted with caution due to the
different study periods and possible differences in the
patient populations included, such as sensitization patterns,
amongst others [9]. The proportion of patients (28.4%)
with ADRs in the group of patients treated with con-
comitant SLIT in our study was observed to be slightly
higher than the proportion of patients (25.3%) treated with
concomitant SCIT. The observation period of our study
included the up-dosing period by five injections and three
maintenance injections with the primary SCIT product
because ADRs are expected to occur with the highest fre-
quency during the initial phase of SCIT treatment.
Reflecting the general use of AIT in Germany, the majority
of patients were treated with the primary SCIT and one
concomitant SCIT product, fewer patients with a single
concomitant SLIT product and only in rare cases with more
than one concomitant AIT product.
In a study with a similar design investigating the
tolerability of the SQ grass SLIT-tablet applied with
concomitant AIT, no change in the tolerability profile or
increase in the frequency of adverse reactions compared
with previous studies with the same product have been
observed [5]. No concomitant AIT treatment has been
recorded in 11.7% of patients treated with the primary
SCIT. The data for this subgroup are displayed
separately.
The open-label, uncontrolled, observational design of
our study performed in real life has its limitations. Physi-
cian’s practices that were distributed all over Germany
participated in the study to minimize a potential










Patients 271 36 307
AEs, total 92 (33.9), 727 10 (27.8), 71 102 (33.2), 798
Primary SCIT discontinued 8 (3.0), 21 2 (5.6), 13 10 (3.3), 34
ADRs, possibly related to AVANZ 63 (23.2), 441 8 (22.2), 64 71 (23.1), 505
Treated by medication 26 (9.6), 147 6 (16.7), 19 32 (10.4), 166
Severity: mild 16 (5.9), 196 –, 15 16 (5.2), 211
Moderate 24 (8.9), 146 1 (2.8), 26 25 (8.1), 172
Severe 23 (8.5), 94 7 (19.4), 23 30 (9.8), 117
Missing value –, 5 – –, 5
Serious 1 (0.4), 4 – 1 (0.3), 4
Primary SCIT discontinued 6 (2.2), 19 2 (5.6), 11 8 (2.6), 30
AE adverse event, ADR adverse drug reaction, AIT allergy immunotherapy, E number of events, SCIT subcutaneous immunotherapy, SLIT
sublingual immunotherapy







Patients 271 198a 81a
ADRs, possibly related to concomitant AIT 69 (25.5), 534 50 (25.3), 361 23 (28.4), 232
Treated by medication 29 (10.7), 141 22 (11.1), 86 9 (11.1), 65
Severity: mild 17 (6.3), 271 12 (6.1), 185 6 (7.4), 119
Moderate 29 (10.7), 177 19 (9.6), 112 10 (12.3), 77
Severe 23 (8.5), 84 19 (9.6), 62 7 (8.6), 36
Missing value –, 2 –, 2 –
Serious 1 (0.4), 4 1 (0.5), 4 1 (1.2), 4
Primary SCIT discontinued 5 (1.8), 15 4 (2.0), 13 4 (4.9), 14
ADR adverse drug reaction, AIT allergy immunotherapy, E number of events, SCIT subcutaneous immunotherapy, SLIT sublingual
immunotherapy
a Including eight patients with combinations of SCIT and SLIT
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Table 5 ADRs related to primary and concomitant AIT in C2 patients in any treatment group










Patients, n 271 198a 81a 271
Patients with ADRs 63 (23.2), 441 50 (25.3), 361 23 (28.4%), 232 69 (25.5), 534
Ear and labyrinth disorders 2 (0.7), 4 – 5 (6.2), 13 5 (1.8), 13
Ear pruritus 1 (0.4), 1 – 5 (6.2), 13 5 (1.8), 13
Eye disorders 8 (3.0), 12 4 (2.0), 4 3 (3.7), 6 5 (1.8), 8
Eye irritation 2 (0.7), 6 1 (0.5), 1 1 (1.2), 4 2 (0.7), 5
Eye swelling 3 (1.1), 3 1 (0.5), 1 – 1 (0.4), 1
Eyelid oedema 2 (0.7), 2 2 (1.0), 2 2 (2.5), 2 2 (0.7), 2
Gastrointestinal disorders 6 (2.2), 8 1 (0.5), 1 12 (14.8), 73 13 (4.8), 74
Glossodynia 1 (0.4), 1 – 2 (2.5), 3 2 (0.7), 3
Lip pruritus – – 2 (2.5), 8 2 (0.7), 8
Lip swelling – – 3 (3.7), 5 3 (1.1), 5
Oedema mouth – – 2 (2.5), 8 2 (0.7), 8
Oral discomfort – – 2 (2.5), 4 2 (0.7), 4
Oral pruritus 1 (0.4), 1 1 (0.5), 1 5 (6.2), 11 6 (2.2), 12
Paraesthesia oral 1 (0.4), 1 – 4 (4.9), 12 4 (1.5), 12
Tongue pruritus – – 4 (4.9), 8 4 (1.5), 8
General disorders and administration site conditions 48 (17.7), 221 40 (20.2), 222 10 (12.3), 48 46 (17.0), 242
Fatigue 6 (2.2), 41 3 (1.5), 28 2 (2.5), 11 5 (1.8), 39
Feeling hot 3 (1.1), 6 3 (1.5), 8 2 (2.5), 8 4 (1.5), 10
Injection site erythema 3 (1.1), 5 4 (2.0), 5 – 4 (1.5), 5
Injection site pain 5 (1.8), 6 8 (4.0), 10 1 (1.2), 1 8 (3.0), 10
Injection site pruritus 13 (4.8), 40 8 (4.0), 29 1 (1.2), 1 9 (3.3), 30
Injection site swelling 6 (2.2), 14 6 (3.0), 11 – 6 (2.2), 11
Injection site warmth 2 (0.7), 3 3 (1.5), 7 1 (1.2), 3 3 (1.1), 7
Local swelling 16 (5.9), 35 15 (7.6), 46 2 (2.5), 12 15 (5.5), 46
Oedema peripheral 9 (3.3), 38 8 (4.0), 38 2 (2.5), 3 10 (3.7), 41
Pain 5 (1.8), 7 5 (2.5), 7 1 (1.2), 1 5 (1.8), 7
Swelling 8 (3.0), 12 7 (3.5), 18 4 (4.9), 7 9 (3.3), 21
Immune system disorders 5 (1.8), 5 3 (1.5), 3 2 (2.5), 2 3 (1.1), 3
Anaphylactic reaction 4 (1.5), 4 3 (1.5), 3 2 (2.5), 2 3 (1.1), 3
Infections and infestations 2 (0.7), 5 1 (0.5), 2 2 (2.5), 6 3 (1.1), 8
Nasopharyngitis 2 (0.7), 5 1 (0.5), 1 1 (1.2), 4 2 (0.7), 5
Musculoskeletal and connective tissue disorders 7 (2.6), 12 4 (2.0), 6 1 (1.2), 5 5 (1.8), 11
Pain in extremity 5 (1.8), 9 3 (1.5), 4 1 (1.2), 5 4 (1.5), 9
Nervous system disorders 5 (1.8), 10 2 (1.0), 3 4 (4.9), 7 6 (2.2), 10
Dizziness 3 (1.1), 3 1 (0.5), 1 – 1 (0.4), 1
Headache 2 (0.7), 5 – 2 (2.5), 5 2 (0.7), 5
Respiratory, thoracic and mediastinal disorders 16 (5.9), 48 11 (5.6), 21 16 (19.8), 42 25 (9.2), 57
Cough 3 (1.1), 12 3 (1.5), 3 3 (3.7), 6 6 (2.2), 9
Dyspnoea 5 (1.8), 12 5 (2.5), 6 3 (3.7), 4 6 (2.2), 7
Nasal congestion 3 (1.1), 3 2 (1.0), 2 2 (2.5), 2 3 (1.1), 3
Pharyngeal oedema 3 (1.1), 3 1 (0.5), 1 2 (2.5), 2 3 (1.1), 3
Rhinorrhoea 2 (0.7), 5 2 (1.0), 5 – 2 (0.7), 5
Sneezing 4 (1.5), 6 2 (1.0), 2 2 (2.5), 4 4 (1.5), 6
Throat irritation 1 (0.4), 1 – 7 (8.6), 19 7 (2.6), 19
Skin and subcutaneous disorders 33 (12.2), 105 28 (14.1), 94 7 (8.6), 28 32 (11.8), 103
Erythema 12 (4.4), 23 8 (4.0), 26 3 (3.7), 12 10 (3.7), 29
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investigator bias. Physicians were instructed to include
patients in a consecutive order to reduce a potential
selection bias. By evaluating 271 patients who received a
concomitant AIT treatment and for which data on safety
and tolerability were recorded ADRs with an incidence of
2% with a probability of 95% can be detected at least once.
This only allows the comparison of ADRs with data from
previous studies of similar design that have included pri-
marily patients treated with one single allergen product in
terms of frequency of ADRs, and safety and tolerability
profiles for those ADRs that have been identified to occur
with the highest frequency for the primary SCIT. The
duration of our study was short compared with the 3-year
treatment term that is recommended for a complete AIT
treatment.
5 Conclusions
In conclusion, frequency of ADRs was not considerably
increased in the present study compared with data from a
previous large non-interventional study with a low pro-
portion of patients who received a concomitant AIT, and
no change in the tolerability profile was observed when
SCIT (AVANZ) was administered with concomitant
SCIT or SLIT.
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